A Brief Talk on Intracavitary Radiotherapy for Gynecological Tumors

A Brief Talk on Intracavitary Radiotherapy for Gynecological Tumors

Intracavitary brachytherapy (ICBT) is a crucial treatment modality for gynecological malignancies (such as cervical cancer, endometrial cancer, and vaginal cancer, etc.). It involves placing radioactive sources directly into natural body cavities adjacent to the tumor (e.g., uterine cavity, vagina), delivering high-dose radiation locally while minimizing damage to surrounding normal tissues. The following section provide a detailed introduction:

I. Overview and Principles

Intracavitary radiotherapy is a type of brachytherapy. Its core principle involves placing radioactive sources (e.g., iridium-192, cobalt-60) directly near the tumor target area, leveraging the rapid dose fall-off with distance to achieve a "high dose to the target while sparing surrounding tissues" effect.

Applicable cancers: Primarily used for cervical cancer (especially locally advanced cases), but also for adjuvant or palliative treatment of endometrial cancer and vaginal cancer.

Treatment goals: Curative intent (in combination with external beam radiation), adjuvant therapy (to reduce recurrence risk), or palliative care (to control bleeding or pain).

II. Indications

1. Cervical Cancer

(1) Definitive treatment for stage IB-IVA cervical cancer (in combination with external beam radiotherapy).

(2) Adjuvant therapy for postoperative high-risk factors (e.g., positive margins, lymph node metastasis).

(3) Vaginal cuff irradiation for intermediate to high-risk endometrial cancer patients after surgery (e.g., deep myometrial invasion, high-grade tumors).

2. Vaginal Cancer

Definitive radiotherapy for early-stage vaginal cancer.

Local boost irradiation for advanced cases.

III. Technical Approaches

Applicator Types

Intrauterine Tandem + Vaginal Applicators (e.g., Fletcher-Suit System)

Used for cervical cancer, designed to conform to uterine anatomy.

Vaginal Cylinders

Applied for postoperative vaginal cuff irradiation in endometrial cancer.

IV. Image-Guided Techniques

2D Planning

Based on X-ray localization using point-dose calculations (e.g., Point A, Point B)

Advantage: Simple to perform.              

Limitation: Lower precision.

3D Planning (3D-IGBT)

Utilizes CT/MRI-guided target delineation (e.g., GTV, CTV) for optimized dose distribution.

Advantage: Significantly reduces radiation exposure to rectum and bladder.

Dose Rate Modes

High-Dose Rate (HDR)

Short-duration single fractions (minutes per session).

Requires multiple outpatient sessions.

Pulsed-Dose Rate (PDR):

Mimics traditional low-dose rate (LDR) brachytherapy.

Suitable for special cases (e.g., large tumor volume).

V. Advantages and Limitations

Advantages:

High local control rate (e.g., >90% 5-year local control for cervical cancer).

Superior organ sparing (e.g., bladder, rectum).

Shorter treatment duration (HDR can be performed outpatient).

Limitations:

Strict patient selection required (e.g., large tumor volume may hinder applicator placement).

Technically demanding (3D planning requires collaboration between imaging and physics teams).

VI. Complication Management

Acute side effects:

Radiation proctitis/cystitis (managed symptomatically).

Late complications:

Vaginal stenosis (requires long-term dilator therapy).

Rectal/bladder fistula (rare, may require surgical repair).

Ovarian failure (ovarian transposition should be considered for young patients).

VII. Advances and Future Directions

Imaging advancements: MRI real-time guidance, AI-assisted target delineation.

Novel radiation sources: Longer half-life isotopes (e.g., Ytterbium-169, Yb-169).

Personalized therapy: Dose optimization based on molecular subtypes (e.g., radiosensitive tumors).

Combination therapy: Synergy with immunotherapy/targeted agents (e.g., PD-1 inhibitors for radiosensitization).

VIII. Conclusion

Intracavitary brachytherapy holds an irreplaceable position in gynecologic oncology, particularly in the definitive treatment of cervical cancer. With advancements in imaging technology and radiation physics, 3D individualized treatment approaches have significantly improved therapeutic efficacy while reducing complications. Looking ahead, multidisciplinary collaboration and technological innovation will further drive its evolution toward precision medicine.

​​Department Introduction​

Radiotherapy Department IV​​ specializes in the treatment of gynecological and breast malignancies using photon and carbon ion therapy. This includes cervical cancer, endometrial cancer, vaginal cancer, vulvar cancer, ovarian cancer, and breast cancer. The department offers radical radiotherapy, preoperative neoadjuvant radiotherapy, postoperative adjuvant radiotherapy, chemotherapy, immunotherapy, targeted therapy, endocrine therapy, and comprehensive treatment integrating these modalities.

The department consists of 13 medical staff, including 2 associate senior titles, 1 attending physician, and 3 resident physicians. Team members have pursued advanced training at renowned institutions such as Tianjin Cancer Hospital, Beijing Cancer Hospital, Beijing 301 Hospital, Peking University Third Hospital, Shanghai Proton and Heavy Ion Hospital, and Sichuan Cancer Hospital.

​​Director of the Department​​: Dang Youquan, Associate Chief Physician, has 24 years of experience in tumor radiotherapy. He has trained in top-tier hospitals nationwide and is highly skilled in radiotherapy and comprehensive treatment for gynecological and breast malignancies. His professional roles include:

Committee Member of the Ion Radiotherapy Branch of the China Medical Equipment Association

Executive Council Member of the Western Oncology Specialty Alliance

Standing Committee Member of the Gansu Anti-Cancer Association’s Brachytherapy Committee

Committee Member of the Gansu Geriatrics Society’s Radiation Oncology Branch

Member of the Gansu Nutrition Society’s Oncology Nutrition Branch

Part-time Lecturer at Wuwei Vocational College

The department collaborates with international experts, including ​​Prof. Jorg Hauffe​​ from the Munich Proton Therapy Center (Germany), ​​Prof. Hironobu Yasui​​ (pioneer in global heavy-ion cancer therapy, Japan), and ​​Prof. Yee-Min Jen, former Chairman of the Taiwan region’s Radiation Oncology Committee. Clinical and academic activities are guided by ​​Prof. Zi Liu​​ (Chair of Gynecologic Oncology at Xi’an Jiaotong University First Affiliated Hospital) and ​​Prof. Sha Li​​ (Chief Radiotherapist at PLA 940th Hospital).

​​Achievements​​:

Completed 5 provincial and municipal-level scientific research projects

Published over 10 research papers

Holds 3 invention patents

​​Advanced Technologies​​:

The department employs cutting-edge techniques, including:

Heavy-ion radiotherapy

Image-Guided Intensity-Modulated Radiotherapy (IGRT)

Volumetric Modulated Arc Therapy (VMAT/RapidArc)

4D Dynamic Radiotherapy

Stereotactic Radiotherapy (SRS/SBRT)

Intensity-Modulated Radiotherapy (IMRT)

3D Conformal Radiotherapy (3DCRT)

Image-guided 3D Brachytherapy

3D-Printed Template-Guided Interstitial Brachytherapy

Bladder Volume Measurement-Guided Precision Radiotherapy for Gynecologic Tumors

Preoperative and Postoperative Radiotherapy

These technologies are integrated with surgery, chemotherapy, hyperthermia, molecular targeted therapy, immunotherapy, and traditional Chinese medicine to establish evidence-based, multidisciplinary cancer treatment protocols. Over the years, the department’s effective comprehensive therapies have achieved remarkable outcomes, earning widespread recognition from peers, patients, and society.